Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Drop in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 26,405 shares, a decline of 86.1% from the May 14th total of 189,821 shares. Based on an average daily volume of 341,001 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ALPMY shares. Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Smbc Nikko Sec. upgraded Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. Finally, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 25th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Astellas Pharma Price Performance

Shares of Astellas Pharma stock opened at $13.32 on Friday. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23. The company has a market cap of $24.10 billion, a PE ratio of 12.40 and a beta of 0.07. The business has a 50 day moving average of $14.87 and a 200 day moving average of $14.61. Astellas Pharma has a 52 week low of $9.11 and a 52 week high of $17.35.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Monday, April 27th. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.28 billion. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%. As a group, equities research analysts forecast that Astellas Pharma will post 1.34 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).